Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$0.83 - $1.18 $30,324 - $43,112
-36,536 Reduced 96.14%
1,465 $1,000
Q1 2023

May 18, 2023

BUY
$0.8 - $4.98 $29,228 - $181,949
36,536 Added 2493.92%
38,001 $30,000
Q1 2023

May 11, 2023

SELL
$0.8 - $4.98 $17,132 - $106,646
-21,415 Reduced 93.6%
1,465 $1,000
Q4 2022

Feb 13, 2023

SELL
$1.88 - $36.45 $1,423 - $27,592
-757 Reduced 3.2%
22,880 $54,000
Q3 2022

Nov 14, 2022

BUY
$2.5 - $37.95 $2,890 - $43,870
1,156 Added 5.14%
23,637 $53,000
Q2 2022

Aug 11, 2022

SELL
$1.75 - $11.34 $19,799 - $128,300
-11,314 Reduced 33.48%
22,481 $55,000
Q1 2022

May 11, 2022

BUY
$10.21 - $20.29 $51,274 - $101,896
5,022 Added 17.45%
33,795 $345,000
Q4 2021

Feb 10, 2022

BUY
$16.76 - $22.99 $96,319 - $132,123
5,747 Added 24.96%
28,773 $568,000
Q3 2021

Nov 12, 2021

BUY
$13.15 - $22.56 $302,791 - $519,466
23,026 New
23,026 $425,000

Others Institutions Holding PRAX

# of Institutions
1
Shares Held
75K
Call Options Held
0
Put Options Held
0

About Praxis Precision Medicines, Inc.


  • Ticker PRAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,576,100
  • Market Cap $3.54B
  • Description
  • Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...
More about PRAX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.